

Investor Presentation

TD Cowen 46th Annual Healthcare Conference

March 4, 2026

Safe Harbor Statement

This presentation and webcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's future financial performance; Cytek's business and operational strategies; the forecasted cell analysis market size and Cytek's market opportunities; Cytek's product plans; Cytek's anticipated 2026 growth drivers; and Cytek's potential for growth and profitability. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or the negatives of these terms or variation of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, without limitation, global geopolitical, economic and market conditions; Cytek's ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to recognize the anticipated benefits of collaborations; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek's ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek's ability to increase penetration in its existing markets and expand into adjacent markets; Cytek's ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek's ability to successfully develop and introduce new products; Cytek's ability to maintain, protect and enhance its intellectual property; Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the "SEC") on February 26, 2026, and other filings Cytek makes with the SEC from time to time. Unless otherwise indicated, these forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Cytek, Cytek Aurora, Northern Lights, Guava, Muse and Amnis are trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders.

Empowering scientific communities with leading cell analysis tools



Cytek 2025 at a Glance ⁽¹⁾

Validated Technology Platform

3,664

Units Placed

>3,500

Cytek FSP™ Peer-reviewed Publications

Broad Customer Base & Global Presence

2,950

Customers

76

Countries

Strong Financial Profile



\$201.5M

2025 Total Revenue

\$261.5M

Cash & Marketable Securities

Global Scale and Reach with Diversified Revenue Mix (1)



1. Full year 2025
 2. EMEA = Europe, Middle East, & Africa
 3. APAC = Asia-Pacific; Rest of World = Canada, Latin America, and other non-specified regions

Flow Cytometry: An Essential Tool in Many Diverse Applications

Flow cytometry is a must-have capability underpinning key decisions for cell-based experiments, production runs, and clinical workflows.

Core Labs, CROs, and cell-therapy manufacturing groups rely on high-utilization flow cytometers that require uptime, redundancy, and harmonization.

Expanding immune research and advanced therapies are increasing cytometry content per study, driving higher utilization and recurring revenue pull-through of reagents and service.

Broad Applicability

Cell + Gene Therapies

Drug Discovery

Cell line development

Translational assays

Immuno-Oncology

Genomics


Immune profiling

Clinical (inc. MRD)

>3,500

Customer Peer-Reviewed
Publications

Large and Growing Global Cell Analysis Market Addressable by Flow Cytometry ⁽¹⁾



Comprehensive Portfolio of Best-in-Class Cell Analysis Tools

Aurora Evo



Cytek Aurora



Aurora Cell Sorter



Northern Lights



Guava



Muse Micro



Amnis




Reagents



Cytek Cloud



Services



Our Strategic Business Pillars

Instruments

Performance

Intelligence

Harmonization

Reliability

Cost Effective

Applications

Reagents

Enabler

Flexibility

Functionality

Recurring Revenue

Bioinformatics

Cytek Cloud

Analysis / AI

Optimization

Management

Exchanges

Clinical ⁽¹⁾

Regulatory

LDT

Menu Driven

AI

Standardization

2026 Growth Drivers

Growth in installed base to drive Service growth

Growth in Reagents driven by expanding market share

Flow cytometry market growth

Innovative new products

Conventional flow cytometer replacement cycle

Cytek Cloud to improve workflows and utilization

Clinical expansion in EMEA and in China



Thank You